Definitive Healthcare (DH) Stock Forecast & Price Target

$4.78

+0.22 (+4.82%)

(As of 12:58 PM ET)

Definitive Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 11 Analyst Ratings

Based on 11 Wall Street analysts who have issued ratings for Definitive Healthcare in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 1 has given a sell rating, 7 have given a hold rating, and 3 have given a buy rating for DH.

Consensus Price Target

$5.81
21.60% Upside

High Forecast	$8.00
Average Forecast	$5.81
Low Forecast	$4.00

According to the 11 analysts' twelve-month price targets for Definitive Healthcare, the average price target is $5.81. The highest price target for DH is $8.00, while the lowest price target for DH is $4.00. The average price target represents a forecasted upside of 21.60% from the current price of $4.78.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.81	$5.64	$9.94	$12.69
Forecasted Upside	21.60% Upside	35.32% Upside	29.37% Upside	19.30% Upside

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

DH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Definitive Healthcare Stock vs. The Competition

Type	Definitive Healthcare	Medical Companies	S&P 500
Consensus Rating Score	2.18	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	27.47% Upside	1,006.91% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	BTIG Research 2 of 5 stars	D. Larsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00	+57.66%
8/9/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Lower Target	Hold ➝ Hold	$7.00 ➝ $5.00	+27.23%
8/7/2024	Robert W. Baird 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$6.00 ➝ $5.00	+32.63%
8/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $4.00	+6.10%
8/6/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$9.00 ➝ $5.00	+36.99%
8/6/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
Central Bank Abandons USD (Ad) Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide.
7/31/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$9.50 ➝ $7.50	+128.66%
7/31/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$7.00 ➝ $5.00	-12.89%
5/14/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/8/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$10.00 ➝ $8.00	+58.42%
8/16/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$17.00 ➝ $10.50	+3.65%
8/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$12.00 ➝ $10.50	+0.19%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$19.00 ➝ $15.00	+26.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:30 PM ET.

DH Forecast - Frequently Asked Questions

What is Definitive Healthcare's forecast for 2024?: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Definitive Healthcare is $5.81, with a high forecast of $8.00 and a low forecast of $4.00.
Should I buy or sell Definitive Healthcare stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Definitive Healthcare in the last twelve months. There is currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DH, but not buy additional shares or sell existing shares.
Does Definitive Healthcare's stock price have much upside?: According to analysts, Definitive Healthcare's stock has a predicted upside of 38.27% based on their 12-month stock forecasts.
Has Definitive Healthcare been downgraded by Wall Street analysts recently?: Over the previous 90 days, Definitive Healthcare's stock had 1 downgrade by analysts.
What analysts cover Definitive Healthcare?: Definitive Healthcare has been rated by research analysts at Barclays, BTIG Research, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Robert W. Baird, and Stifel Nicolaus in the past 90 days.
Do Wall Street analysts like Definitive Healthcare more than its competitors?: Analysts like Definitive Healthcare less than other "medical" companies. The consensus rating for Definitive Healthcare is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DH compares to other companies.